<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387721</url>
  </required_header>
  <id_info>
    <org_study_id>EC042019</org_study_id>
    <secondary_id>2019/65-OFT-CMT</secondary_id>
    <nct_id>NCT04387721</nct_id>
  </id_info>
  <brief_title>Influence of Residual Astigmatism on Visual Acuity in Patients Undergoing Cataract Surgery With Trifocal Intraocular Lens Implantation</brief_title>
  <official_title>Influence of Residual Astigmatism on Visual Acuity in Patients Undergoing Cataract Surgery With Trifocal Intraocular Lens Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enrique Ordiñaga-Monreal, OD, MSc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Oftalmologica TACIR</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAIN OBJECTIVE: To assess the influence of residual astigmatism on visual acuity in the
      different lens foci in patients operated on for cataracts with a trifocal intraocular lens
      implant.

      SECONDARY OBJECTIVE: To study the influence of residual astigmatism on the visual quality of
      the patient in the far focus and to determine if there are differences of affectation in the
      two study groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be studied how small residual astigmatisms after cataract surgery degrade the visual
      acuity of patients in the three focal planes of trifocal IOLs. Not only VA will be studied,
      but also visual quality through contrast sensitivity curves.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>3 months following cataract surgery</time_frame>
    <description>Visual acuity will be measured at distance, intermediate distance (67 cm) and near (40 cm). Visual acuities will be obtained with logarithmic notation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast Sensitivity Function (CSF)</measure>
    <time_frame>3 months following cataract surgery</time_frame>
    <description>Contrast sensitivity will be measured at far, intermediate distance (67 cm) and near (40 cm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences between groups</measure>
    <time_frame>3 months following cataract surgery</time_frame>
    <description>Results will be compared between groups.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cataract After</condition>
  <condition>Astigmatism</condition>
  <condition>IOL</condition>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Trifocal IOL(Finevision IOL, PhysIOL)</arm_group_label>
    <description>We will divide the sample into two groups of patients depending on the IOL implanted First group: FineVision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trifocal toric IOL (Finevision Toric IOL, PhysIOL)</arm_group_label>
    <description>We will divide the sample into two groups of patients depending on the IOL implanted: Second group: FineVisionToric</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kind of trifocal IOL</intervention_name>
    <description>Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D</description>
    <arm_group_label>Trifocal IOL(Finevision IOL, PhysIOL)</arm_group_label>
    <arm_group_label>Trifocal toric IOL (Finevision Toric IOL, PhysIOL)</arm_group_label>
    <other_name>FineVision IOL</other_name>
    <other_name>FineVision Toric IOL</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The field in which it will carry out the study is a private medical centre. TACIR
        Ophthalmology clinic is located in the TEKNON Medical Center in the city of Barcelona. The
        study population will be the patients of the TACIR ophthalmology clinic who will be
        operated on cataracts and agree to take part in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bilateral surgery performed by the same surgeon

          -  IOLs implanted IOLs FineVision (MicroF) and FineVision Toric (PodFT)

          -  Patients with pre-surgery corneal astigmatism less than 2.5 D

          -  Patients whose pupillary diameter in physiological position (conditions of lower
             photopic pupil) not over 4 mm.

        Exclusion Criteria:

          -  Post-surgical refractive residual astigmatisms ≧ 1.55D

          -  Previous corneal or intraocular surgeries

          -  Active diseases

          -  Eye complications during the 3-month follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Ordiñaga-Monreal, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Oftalmologica TACIR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrique Ordiñaga-Monreal, OD</last_name>
    <phone>934179803</phone>
    <email>e.ordinaga@clinicatacir.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Oftalmológica TACIR</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ordiñaga-Monreal Enrique, OD</last_name>
      <phone>934179803</phone>
      <email>e.ordinaga@clinicatacir.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Oftalmologica TACIR</investigator_affiliation>
    <investigator_full_name>Enrique Ordiñaga-Monreal, OD, MSc</investigator_full_name>
    <investigator_title>Clinical Optometrist</investigator_title>
  </responsible_party>
  <keyword>CSF</keyword>
  <keyword>Contrast Sensitivity</keyword>
  <keyword>Trifocal IOL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04387721/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04387721/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

